Tested Applications
| Positive FC detected in | human PBMCs |
Recommended dilution
| Application | Dilution |
|---|---|
| Flow Cytometry (FC) | FC : 5 ul per 10^6 cells in a 100 µl suspension |
| This reagent has been pre-titrated and tested for flow cytometric analysis. The suggested use of this reagent is 5 ul per 10^6 cells in a 100 µl suspension or 5 ul per 100 µl of whole blood. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
PE-98717 targets CCR7 in FC applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen |
unknow Predict reactive species |
| Full Name | chemokine (C-C motif) receptor 7 |
| Gene Symbol | CCR7 |
| Gene ID (NCBI) | 1236 |
| Conjugate | PE Fluorescent Dye |
| Excitation/Emission Maxima Wavelengths | 496 nm, 565 nm / 578 nm |
| Excitation Laser | Blue Laser (488 nm), Green Laser (532 nm), Yellow-Green Laser (561 nm) |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | P32248 |
| Storage Buffer | PBS with 0.09% sodium azide and 0.5% BSA, pH 7.3. |
| Storage Conditions | Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment. |
Background Information
C-C chemokine receptor type 7 (CCR7), which belongs to the G-protein coupled receptor 1 family, is also a receptor for the MIP-3-beta chemokine, and probably acts as a mediator of EBV effects on B-lymphocytes or of normal lymphocyte functions. CCR7 is specially expressed in various lymphoid tissues and activated B- and T-lymphocytes, and can be strongly up-regulated in B-cells infected with Epstein-Barr virus and T-cells infected with herpesvirus 6 or 7.
Publications
What published studies show
PE-98717 is an Anti-Human CCR7 Rabbit Recombinant Antibody (clone 253310A1). It has 1 total citation, published in Journal of Translational Medicine (J Transl Med). The cited study investigates autocrine PD-1-blocking nanobodies enhancing antitumor efficacy of TCR-like CAR-T cells by attenuating T cell exhaustion, placing this antibody's use in the fields of immunotherapy, CAR-T cell engineering, and tumor immunology.
| Species | Application | Title |
|---|---|---|
J Transl Med Autocrine PD-1-blocking nanobodies enhance the antitumor efficacy of TCR-like CAR-T cells by attenuating t cell exhaustion. |
